GW Pharmaceuticals to Report Interim 2013 Results and Host Conference Call on June 3, 2013
5/14/2013 7:13:54 AM
More...
|
GW Pharmaceuticals Announces the Closing of Its Initial Public Offering on the Nasdaq Global Market
5/8/2013 10:19:13 AM
More...
|
GW Pharmaceuticals Announces Sativex® Commercialization Approval in Italy
5/7/2013 9:32:40 AM
More...
|
GW Pharmaceuticals Announces Pricing of Initial Public Offering on the NASDAQ Global Market
5/1/2013 11:01:24 AM
More...
|
GW Pharmaceuticals Announces U.S. Patent Allowance for SATIVEX® Formulation Spray Device
4/22/2013 9:34:46 AM
More...
|
GW Pharmaceuticals' Cannabinoid-Medicine Sativex® Moved to Schedule 4 of UK Drugs Act
4/10/2013 9:54:11 AM
More...
|
GW Pharmaceuticals, Almirall May Pull Cannabis Drug in German Price Row
3/19/2013 11:50:50 AM
More...
|
GW Pharmaceuticals Appoints Stephen D. Schultz as Vice President of Investor Relations
3/19/2013 11:23:52 AM
More...
|
GW Pharmaceuticals Files Registration Statement for NASDAQ Global Market Listing and U.S. Initial Public Offering
3/19/2013 10:24:13 AM
More...
|
GW Pharmaceuticals Sativex(R) Launched in Denmark
7/18/2011 9:23:49 AM
More...
|
|